Akari Therapeutics (NASDAQ:AKTX) had its price target cut by equities researchers at Canaccord Genuity from $15.00 to $8.00 in a report released on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s target price would indicate a potential upside of 339.56% from the stock’s previous close.
Several other analysts have also recently weighed in on AKTX. B. Riley began coverage on shares of Akari Therapeutics in a research note on Thursday, February 8th. They issued a “neutral” rating and a $3.00 price objective on the stock. Zacks Investment Research cut shares of Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Finally, ValuEngine raised shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $4.63.
Shares of Akari Therapeutics stock opened at $1.82 on Thursday. Akari Therapeutics has a twelve month low of $1.70 and a twelve month high of $22.20.
Institutional investors have recently modified their holdings of the stock. Endurant Capital Management LP bought a new stake in shares of Akari Therapeutics in the fourth quarter worth $871,000. Millennium Management LLC grew its stake in shares of Akari Therapeutics by 125.0% in the fourth quarter. Millennium Management LLC now owns 260,020 shares of the biopharmaceutical company’s stock worth $1,126,000 after purchasing an additional 144,477 shares during the last quarter. Finally, AWM Investment Company Inc. bought a new stake in shares of Akari Therapeutics in the fourth quarter worth $2,962,000. 32.94% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was first posted by WKRB News and is owned by of WKRB News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.wkrb13.com/2018/03/31/akari-therapeutics-aktx-pt-lowered-to-8-00.html.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.